Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation

Thorax

Volumn 59, Issue 12, 2004, Pages 1016-1019

  Carpagnano, G E ^b   Kharitonov, S A ^a   Foschino Barbaro, M P ^c   Resta, O ^b   Gramiccioni, E ^b   Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; INTERLEUKIN 6; ISOPROSTANE; OXYGEN; UNCLASSIFIED DRUG;

ADULT; AIRWAY; ARTICLE; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EXHALATION; FACE MASK; FEMALE; HUMAN; HYPEROXIA; IMMUNOASSAY; INFLAMMATION; LONG TERM CARE; MALE; OXIDATIVE STRESS; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT OUTCOME;

BRONCHITIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOASSAY; INTERLEUKIN-6; ISOPROSTANES; MALE; MIDDLE AGED; OXIDATIVE STRESS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 9644262505     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2003.020768     Document Type: Article

References (15)

1. Morcillo E, Estrela J, Cortijo J. Oxidative stress and pulmonary inflammation: pharmacological intervention with antioxidants. Pharmacol Res 1999;40:394-404.
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
3. Mantell LL, Lee PJ. Signal transduction pathways in hyperoxia-induced lung cell death. Mol Genet Metab 2000;71:359-70.
4. 2 in human divers. Undersea Hyperb Med 1999;26:159-64.
5. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001;280:L1067-82.
6. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
7. 2α production by alveolar macrophages exposed to hyperoxia. Shock 1998;9:266-73.
8. Song W, Zhao J, Li Z. Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J 2001;114:1140-2.
9. Carpagnano GE, Kharitonov SA, Resta O, et al. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnoea patients. Chest 2002;122:1162-7.
10. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995;333:710-14.
11. Phillips M, Cataneo RN, Greenberg J, et al. Effect of oxygen on breath markers of oxidative stress. Eur Respir J 2003;21:48-51.
12. Kharitonov SA, Donnelly LE, Montuschi P, et al. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002;57:889-96.
13. Jatokanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.
14. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
15. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999;14:1002-8.